District Court, D. New Jersey September 22, 2022, 2:21-cv-20452 (BERNSTEIN v. BRISTOL-MYERS SQUIBB CO.)

Also known as

United States · · · 22-09-2022

UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF NEW JERSEY

HOWARD BERNSTEIN, on behalf of

himself and all others similarly

situated,

Plaintiff,

v. Civ. No. 21-20452 (KM) (CLW)

BRISTOL-MYERS SQUIBB CO., et al., OPINION

Defendant.

KEVIN MCNULTY, U.S.D.J.:

Plaintiff Howard Bernstein, on behalf of himself and others similarly

situated, filed this putative class action against Defendant Bristol-Myers

Squibb Company (“BMS”) and several of its directors and officers (collectively,

“Defendants”) in New Jersey state court, alleging that the Form S-4 registration

statement BMS filed with the U.S. Securities and Exchange Commission

pertaining to certain Contingent Value Rights (the “Registration Statement”)

was false and misleading, in violation of the Securities Act of 1933, 15. U.S.C. §

77a et seq.

Now before the Court are Defendants’ motion to transfer venue, and

Plaintiff’s motion to remand the case to state court. For the reasons expressed

below, Plaintiff’s motion to remand is GRANTED, and Defendants’ motion to

transfer venue is DENIED.

BACKGROUND

On November 12, 2021, Plaintiff filed the complaint in this action in the

Superior Court of New Jersey, Law Division, Union County. (DE 1 Ex. 2.) The

complaint is related to BMS’s 2019 acquisition of Celgene Corporation, the

consummation of which included BMS issuing approximately 714.9 million

new shares of common stock and 714.9 Contingent Value Rights (“CVRs”) to

former holders of Celgene stock. (DE 1 Ex. 2 ¶ 6.) Plaintiff alleges that the

Registration Statement BMS filed in connection with the acquisition was false

and misleading, in violation of the Securities Act of 1933 (the “’33 Act”),

because it failed to disclose actions BMS was taking that would delay approval

by the Food and Drug Administration of a blockbuster cancer therapy Celgene

had been developing, thereby preventing a $6.4 billion payout promised to CVR

holders. (DE 1 Ex. 2 ¶ 6.

Read the full text

This document is published by courtlistener.com.

Moonlit adds the citation network, article-level links and cross-references, which are available to search for free.